Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed?

Simply Wall St.03-10

Neuren Pharmaceuticals Limited has reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, both materially lower than the prior year’s levels. The sharp...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618604673?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-03-10 07:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618604673","market":"hk","top_or_hot":-1,"title":"Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed?","media":"Simply Wall St.","content":"<div>\n<p>Neuren Pharmaceuticals Limited has reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, both materially lower than the prior year’s levels. The sharp...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-152-after-2025-earning\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-10 07:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-152-after-2025-earning><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neuren Pharmaceuticals Limited has reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, both materially lower than the prior year’s levels. The sharp...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-152-after-2025-earning\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU.AU","symbol_name":"NEUREN PHARMACEUTICALS LTD","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-152-after-2025-earning","article_id":"2618604673","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-is-down-152-after-2025-earning","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618604673","pubTimestamp":1773098455,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Neuren Pharmaceuticals Limited has reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, both materially lower than the prior year’s levels.\nThe sharp reduction in basic earnings per share from continuing operations, from A$1.1117 to A$0.2373, highlights how recent financial performance contrasts with earlier analyst expectations for the business.\nWe’ll now examine how this sharp drop in annual revenue and earnings shapes Neuren...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NEU.AU":"NEUREN PHARMACEUTICALS LTD","NEU":"NewMarket"},"translate_title":"2025年盈利低于预期后，Neuren Pharmaceuticals(ASX：NEU)下跌15.2%牛市情况发生变化了吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1.5,"NEU":1.5},"content_text":"Neuren Pharmaceuticals Limited has reported its full-year 2025 results, with revenue of A$84.84 million and net income of A$30.44 million, both materially lower than the prior year’s levels. The sharp reduction in basic earnings per share from continuing operations, from A$1.1117 to A$0.2373, highlights how recent financial performance contrasts with earlier analyst expectations for the business. We’ll now examine how this sharp drop in annual revenue and earnings shapes Neuren Pharmaceuticals’ previously bullish long-term investment narrative. The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementNeuren Pharmaceuticals Investment Narrative RecapTo own Neuren, you need to believe that DAYBUE royalties and the NNZ-2591 pipeline can justify today’s valuation despite concentrated revenue and regulatory risk. The steep fall in 2025 revenue to A$84.84 million and net income to A$30.44 million sharpens focus on near term DAYBUE performance and Medicaid exposure, but does not by itself change the importance of U.S. patient uptake and progress on new indications as the key short term catalyst. Against this earnings backdrop, Neuren’s recent decision to extend its on market share buyback of up to 6,350,631 shares stands out. While the buyback does not offset the impact of weaker 2025 earnings, it interacts directly with the main catalysts by potentially amplifying the effect of any future DAYBUE or NNZ-2591 driven growth on per share metrics, while also tightening the link between execution risk around Acadia and shareholder outcomes. Yet, beneath the buyback and the DAYBUE story, one underappreciated risk that investors should be aware of is... Read the full narrative on Neuren Pharmaceuticals (it's free!)Neuren Pharmaceuticals’ narrative projects A$166.7 million in revenue and A$228.4 million in earnings by 2028.Uncover how Neuren Pharmaceuticals' forecasts yield a A$23.45 fair value, a 101% upside to its current price.Exploring Other PerspectivesASX:NEU 1-Year Stock Price Chart Before this result, the most optimistic analysts were assuming earnings around A$140.4 million by 2028, yet with revenue now at A$84.84 million, you can see how views on DAYBUE dependence and future earnings stability might widen further, and why it is worth comparing these bullish expectations with your own assumptions.Explore 11 other fair value estimates on Neuren Pharmaceuticals - why the stock might be worth 13% less than the current price!Form Your Own VerdictDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Neuren Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.Our free Neuren Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neuren Pharmaceuticals' overall financial health at a glance.Contemplating Other Strategies?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neuren Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618604673","isCrawlerRequest":true}